Atea Pharmaceuticals, Inc. (AVIR) Financial Statements (2024 and earlier)

Company Profile

Business Address 225 FRANKLIN STREET
BOSTON, MA 02110
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments646,709764,375850,117
Cash and cash equivalents188,460764,375850,117
Short-term investments458,249  
Other undisclosed cash, cash equivalents, and short-term investments   
Receivables   5,815
Other undisclosed current assets14,2138,0287,545
Total current assets:660,922772,403863,477
Noncurrent Assets
Operating lease, right-of-use asset2,389  
Property, plant and equipment1,7052348
Restricted cash and investments 198  
Other noncurrent assets1,494466107
Total noncurrent assets:5,786489155
TOTAL ASSETS:666,708772,892863,632
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9,10911,3152,803
Taxes payable2,572 
Employee-related liabilities4,2092,743
Accounts payable2,5514,53460
Accrued liabilities6,558  
Deferred revenue   301,367
Other undisclosed current liabilities9,36945,56811,625
Total current liabilities:18,47856,883315,795
Noncurrent Liabilities
Liabilities, other than long-term debt7,6585,93236
Accounts payable and accrued liabilities5,255  
Other liabilities  5,93236
Operating lease, liability2,403  
Total noncurrent liabilities:7,6585,93236
Total liabilities:26,13662,815315,831
Equity
Equity, attributable to parent640,572710,077547,801
Common stock838382
Additional paid in capital701,052653,964612,879
Accumulated other comprehensive loss(684)  
Retained earnings (accumulated deficit)(59,879)56,030(65,160)
Total equity:640,572710,077547,801
TOTAL LIABILITIES AND EQUITY:666,708772,892863,632

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Revenues  351,36748,633
Gross profit:  351,36748,633
Operating expenses(130,650)(212,990)(59,663)
Operating income (loss):(130,650)138,377(11,030)
Income (loss) from continuing operations before equity method investments, income taxes:(130,650)138,377(11,030)
Other undisclosed income from continuing operations before income taxes11,151213 
Income (loss) from continuing operations before income taxes:(119,499)138,590(11,030)
Income tax expense (benefit)3,590(17,400) 
Income (loss) from continuing operations:(115,909)121,190(11,030)
Income (loss) before gain (loss) on sale of properties:121,190(11,030)
Other undisclosed net income   83
Net income (loss) available to common stockholders, diluted:(115,909)121,190(10,947)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Net income (loss):(115,909)121,190(10,947)
Other comprehensive income (loss)(684)  
Other undisclosed comprehensive loss   
Comprehensive income (loss):(116,593)121,190(10,947)
Other undisclosed comprehensive income, net of tax, attributable to parent   
Comprehensive income (loss), net of tax, attributable to parent:(116,593)121,190(10,947)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: